Monographie - Pancuronium bromide

最新更新 :
27/04/2026

Pancuronium bromide

化学構造

商品名

商品名、賦形剤は国、製薬会社ごとに異なることがあります

Pancuronium bromide injection

アイルランド, アメリカ, アラブ首長国連邦, イギリス, イラン, エジプト, カナダ, ドイツ, ニュージーランド, フランス, ポーランド

引用文献 : Pancuronium bromide

	形式	出版物
255	雑誌	Ishisaka DY. Visual compatibility of fluconazole with drugs given by continuous infusion. Am J Hosp Pharm 1994 ; 51: 2290,2292.
285	雑誌	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
300	雑誌	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
319	雑誌	Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999.
402	雑誌	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
660	雑誌	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
755	実験	Pancuronium (Pavulon®) - Résumé des caractéristiques du produit MSD France 2016
813	雑誌	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
1057	雑誌	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072	雑誌	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1721	雑誌	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1803	雑誌	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
2079	雑誌	Morton WD, Lerman J. The effect of pancuronium on the solubility of aqueous thiopentone. Can J Anesth 1987 ; 34: 87-89.
2090	雑誌	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	雑誌	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
3152	雑誌	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216	雑誌	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3408	雑誌	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3767	雑誌	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
4773	雑誌	Merienne C, Filali S, Marchand C, Lapras B, Paillet C, Pirot F. Predictive stability, novel HPLC-MS analysis and semi-automatic compounding process for the emergency implementation of a production line of pancuronium in injectable solution. Eur J Pharm Sci 2023 ; 187: 106464.
5011	実験	Hypnomidate 2 mg/ml Injection - Summary of Product Characteristics Updated 02-Apr-2024. Piramal Critical Care Limited 2024
5042	実験	Dexdor 100 micrograms/ml concentrate for solution for infusion - Summary of Product Characteristics. Orion Corporation 2016

Mentions Légales